DATA GRAPHICS | Data Byte
Comparing durability of leading hemophilia A gene therapies
BioMarin, Pfizer-Sangamo products keep patients in the mild disease category for at least two years, though Factor activity wanes
January 13, 2022 1:43 AM UTC
New data provide an updated picture about the durability of hemophilia A gene therapies, showing that although Factor VIII activity wanes, the most advanced programs achieve activity levels that keep patients’ disease mild for at least two years.
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced two-year results from the Phase III GENEr8-1 study of valoctocogene roxaparvovec to treat hemophilia A. ...
BCIQ Target Profiles